Mar 01 2015

Monte Jade Forum (Mar. 2015): Recent Development in Intellectual Property Law and Litigation

Published by admin under Monthly Meeting

  • Event Date: Thursday, March 26, 2015
  • Time: 6:30PM-9:00PM
  • Location: ITRI Int’l, 2870 Zanker Rd., Suite #140, San Jose, CA 95134
  • Speakers:
    Chris Chou (周堅維), IP partner in K&L Gates’ San Francisco Office and former Director of Intellectual Property, Legal for Taiwan Semiconductor Manufacturing Company, Ltd
    Patrick Ellisen, Greenberg Traurig, LLP
  • Moderator: Emil Chang, Managing Attorney, Venture Pacific Law
  • Topics:
    “Powerful and effective IP management strategies in light of a changing legal landscape”;
    “The Patent Office as the Alpha and Omega of patent disputes”;
    “How to slaughter a patent troll; what is working now”
  • Registration: Please register in advance. Click here.
  • Member & Student $10, Non-Member$20, extra $5 for site registration
  • Contact Info: service@montejade.org
  • Light refreshments and drink will be provided.

 

Speaker Bio:

Chris Chou

Chris Chou is an IP partner in K&L Gates’ San Francisco office. He is the former Director of Intellectual Property, Legal for Taiwan Semiconductor Manufacturing Company, Ltd., where he had overall management of intellectual property matters including inter alia, patents and trade secrets. At K&L Gates he is involved in patent litigation, patent application preparation, portfolio management, prosecution, and infringement/validity analysis in the areas of electronics, microprocessor, computer software, computer system/architecture and semiconductor devices/fabrication technologies. He has managed patent dispute matters in Taiwan and the U.S., and negotiated various deals including joint development projects, patent and technology license agreements, and patent acquisition transactions.

 

Patrick Ellisen

Mr. Ellisen’s practice focuses on intellectual property and general commercial litigation, as well as intellectual property protection, counseling and enforcement. He has broad experience handling various types of intellectual property disputes, including patent infringement actions in the U.S. District Courts and before the U.S. International Trade Commission and has particular experience in insurance coverage of intellectual property disputes. Mr. Ellisen also has wide-ranging experience in copyright, trademark and trade secret matters. He regularly advises clients on intellectual property and technology strategies and general business matters and negotiates and litigates intellectual property license agreements. Mr. Ellisen is a frequent lecturer on intellectual property management and best practices. Mr. Ellisen concentrates on Patent infringement; Intellectual property protection, counseling and exploitation; Commercial litigation; Copyright, trademark and trade secret. Mr. Ellisen holds J.D., University of California, Hastings College of the Law, 1989 and B.A., with honors, Political Science, University of California at Berkeley, 1986.

 

No responses yet

Jan 19 2015

Monte Jade Tien’s Forum (Feb. 2015): A Retrospective: Professional and Personal Advice — When Opportunity Knocks, You Gotta Answer

Published by admin under Monthly Meeting

susan

Susan will share her experience in her career path. From her graduation as a foreign student with no supporting network, to her ascendency onto Corporate boards. As she plugged along, without prospects to rise above mid-management level, she was given an opportunity for an acting executive position. She jumped in with both feet and worked to secure the position. Susan will reflect on the lessons learned and talk about giving back as a volunteer mentor today.

 

 

Speaker Bio:

Susan S. Wang

Susan S. Wang retired from Solectron Corporation in 2002 after 18 years, having served as Executive Vice President for Corporate Development, Chief Financial Officer, and Corporate Secretary. She oversaw Solectron’s initial public offering and subsequent growth from a $40 million organization to a global corporation with more than $12 billion in revenue. A CPA, she began her career with Price Waterhouse and earlier held financial and managerial positions with Xerox Corporation and Westvaco Corporation. She currently serves on the Board of Directors and is Audit Committee Chair for Cirrus Logic, Nektar Therapeutics and Premier, Inc. and serves on Cirrus Logic’s Compensation Committee. Previously, Susan served on the Board of Directors of Calpine, Corp., Avanex, Inc., Rae Systems, Inc., Altera Corp. and Suntech Power Holding, Inc.

 

No responses yet

Nov 30 2014

Monte Jade Forum (Jan. 2015): Breakthrough Treatment Options for Diverse Types of Cancer Patients with Immune-oncology Approaches

Published by admin under Monthly Meeting

  • Event Date: Thursday, January 8, 2015
  • Time: 6:30PM-9:00PM
  • Location: ITRI Int’l, 2870 Zanker Rd., Suite #140, San Jose, CA 95134
  • Moderator and Panelists:
    Roxanne Duan, Director, External Collaborations, MedImmune, LLC. (Moderator)
    Cheng Liu, CEO of Eureka Therapeutics, Inc.
    Sonny Hsiao, CEO of Adheren, Inc.
    John C. Lin, VP, Experimental Medicine & Cancer Immunotherapy, Pfizer, Inc.
  • Registration: Please register in advance. Click here.
  • Member & Student $10, Non-Member$20, extra $5 for site registration
  • Contact Info: service@montejade.org
  • Light refreshments and drink will be provided. 

 

This panel discussion will focus on the recent breakthrough treatment options, namely “immune-oncology” approaches, for a variety of cancer. The moderator will give a general introduction of the immmuno-oncology approaches and a few examples of amazingly cancer patient responses, as high as response rate in the 90% range, to immune-oncology therapies. A panel of internationally renowned researchers, clinicians and entrepreneurs will be available to discuss current clinical trials, potential issues, and investment opportunities in immune-oncology therapies for different cancer, as well as hosting a Question & Answer session at the end.

 

Speakers and Moderator Bio:

Roxanne Duan

Dr. Roxanne Duan joined MedImmune in 2012 as Director of External Collaborations. She spearheads external collaborations with academia, government and non-profit organizations and champions the formation of the Brazilian Science without Borders postdoc program at MedI. Before joining MedImmune, Roxanne was Director of External Discovery at GSK China with the goal to bring in assets from academic laboratories. Prior to GSK China, she was VP for R&D at Adlyfe, Inc., working on diagnostic methods and therapeutics for Alzheimer’s disease. Before Adlyfe, Roxanne was VP of R&D at Functional Genetics, Inc. where she led team to the invention and development of broad-spectrum antiviral therapeutics against human targets. Prior to Functional Genetics, Roxanne was a Project Leader at Human Genome Sciences, Inc. She discovered protein drugs from gene sequences and led teams to develop them, resulting in the filing of three protein drug INDs. Roxanne has a Ph.D. degree in Pharmaceutical Chemistry from University of California, San Francisco, did postdoctoral fellowships in tumor suppressor genes at the NIH and in growth factor signalling at HHMI, had extensive experiences in protein and antibody drug discovery. She also took on roles in the Advisory Board of Women in Bio and the head of Chinese Biopharmaceutical Association. Roxanne holds more than 30 original publications, 82 published patents and 26 allowed patents.

 

Cheng Liu

Dr. Cheng Liu is the founder and CEO of Eureka Therapeutics, a California biotech company dedicated to antibody research and discovery for cancer immunotherapy. Prior to founding Eureka, Dr. Liu was a Principal Scientist in antibody drug discovery at Chiron (now Novartis), where he championed anti-CSF1 antibody program for treatment of bone metastasis to human clinical trials. He is the inventor of multiple issued US patents in drug discovery. In 2007, he was awarded Special US Congressional Recognition for his contributions to improving human health.. Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a Ph.D. in Molecular Cell Biology from the University of California, Berkeley.

 

John C. Lin

Dr. John C. Lin is currently Vice President, Experimental Medicine & Cancer Immunotherapy at Pfizer Inc. John has worked at a biotech startup Rinat since 2002, through its acquisition by Pfizer in 2006. Before that he was a postdoctoral fellow at Genentech Inc. from 1999-2001. He obtained a Ph.D. in Biological and Biomedical Sciences from Harvard Medical School in 1998, and his M.D. from the College of Medicine of National Taiwan University in 1992.

 

John is dedicated to developing novel immunotherapeutic agents to address the key mechanisms of serious human diseases. He investigated beta amyloid peptide’s impact on the age-related macular degeneration and Alzheimer’s disease. He conceived of the original idea of passive immunotherapy targeting PCSK9 for LDL lowering in 2006. His team also unveiled the critical roles of the cytokine interleukin 7 in the pathogenesis of multiple sclerosis and type 1 diabetes.

 

In 2013 his research responsibility has expanded into leading the overall strategy of cancer immunology in Pfizer, including checkpoint inhibitors, co-stimulators and CAR T cell therapy. For instance, he is responsible for establishing Pfizer’s collaboration with MD Anderson Cancer Center’s Immunotherapy Platform (Jan 2014), collaboration with Cellectis on CAR-T technology (Jun 2014) and collaboration with Kyowa H. Kirin on 4-1BB / CCR4 combination therapy in solid tumors (Sep 2014).

 

Sonny Hsiao

Dr. Sonny Hsiao is CEO of Adheren, Inc. He manages R&D projects in the development of immunotherapies based on cell-conjugated antibodies for cancer. He also leads the development of a novel technology platform that uses chemical methods to conjugate any therapeutic moiety onto solid surfaces such as silicon, glass or living cells. As a young PI, Sonny is currently managing a NCI-IMAT R33 grant and several collaborations with academic laboratories, including David Schaffer lab at UC Berkeley, Zev Gartner lab at UCSF, Stuart Martin lab at U of Maryland, and Monica Hinds lab at OHSU. Sonny obtained his Ph.D. degree in Chemistry and Chembio from UC Berkeley.

 

No responses yet

Sep 07 2014

24th Monte Jade Annual Conference- How Should We Then Grow?

Published by admin under Annual Conference

  • Event Date: Saturday, September 27, 2014
  • Time: Afternoon Program 1:20pm-4:30pm; Dinner Banquet 6:00pm-9:00pm
  • Location: Michaels At Shoreline, 2960 N Shoreline Blvd, Mountain View, CA 94043
  • Registration: Online registration is required. (https://www.eventbrite.com/e/2014-monte-jade-west-annual-conference-tickets-12680934015).
  • Cost: General Public $150; Monte Jade Member $120. Seating is limited.
  • Contact: service@montejade.org or (408)428-0388 for more information and sponsorship.
  •  

  • Theme: How Should We Then Grow?
  • The 2014 Monte Jade West Annual Conference has the theme of “How Should We Then Grow?” The “grow” related factors such as technologies (“Top Tech Trends”), venture investment (“Venture Beats”), and “Cross-Pacific Dynamics“ are arranged as panel sessions in the afternoon program. You will have the choice of nature walk around the shoreline or putting game to network and enjoy with each other before the evening program.

     

    We are honored to have Ro Khanna as the keynote speaker in the evening program will bring insights and foresights to a bright audience. We will have live band and let the dance floor open into the night.

     

    This is an “un-conference” as the participants will be able to closely engage with the panelist/speakers and fellow colleagues in a beautiful venue (next to a golf course) with small setting and interactive format. Seating is limited to 220 and we expect a large part of it will be taken by our sponsors and their guests as well as our VIPs joining the conference from local, Greater China area and other Monte Jade chapter in North America. It will be a fun “unconference” with great opportunities to meet leaders from various fields, network with talented people, and build up valuable relationships.

     

  • Agenda:
  • 01:20-01:40 pm Opening

    01:40-02:50 pm Afternoon Program-I

    Session 1a. Mobile Health: Calling on Cell Technology for Better Chronic Care
    Chronic conditions take up a staggering 75% of US health care spending; beyond the trillions of dollars in financial burden, the human costs are even more alarming. Effective management of chronic diseases rely on regular monitoring, yet many patients have only a few minutes with their clinicians and little access to actionable information. Mobile technology-based platforms and applications provide powerful tools to assist patients in managing their health care — not only at home, but almost anywhere outside the clinician’s office.

     

    Session Chairs:
    Chu K. Chang, Corporate Strategy and Development, Exogen Biotechnology, Inc.
    Nelson Teng, M.D., Associate Professor, Obstetrics & Gynecology - Gynecologic Oncology, School of Medicine, Stanford University
    Ben C. Hwang, Ph.D., Chairman and CEO, PROFUSA Inc.

     

    Panelists:
    Ben C. Hwang, Ph.D., Chairman and CEO, PROFUSA Inc. (Moderator)
    Connie Chen, M.D., Primary Care Physician, St. Anthony Medical Clinic
    Stanley Yang, Founder and CEO, Neurosky

     

    Session 1b. Living Dry: Emerging Technology Trends in Water Purification and Reuse
    According to the United Nations, “approximately 1.2 billion people live in areas of physical water scarcity. Another 1.6 billion people face economic water shortages (where countries lack the necessary infrastructure to take water from rivers and aquifers).” These grim conditions make fresh water management one of the most pressing social issues of the 21st century. This session will help participants understand the global context for freshwater scarcity and how emerging technology trends in treatment and reuse can be applied to meet those needs. Discussion topics will include factors driving technological development and market opportunities.

     

    Session Chair:
    Katherine Kao Cushing, Ph.D., Associate Professor, San Jose State University

     

    Panelists:
    Michael Hawes, CEO of Liquidity
    Pam John, Senior Engineer at the Santa Clara Valley Water District
    Michael Flynn, Project Director, NASA Ames Research Center
    Joseph Wong, Senior Engineer, Brown and Caldwell
    Katherine Kao Cushing, Ph.D., Associate Professor, San Jose State University (Moderator)

     

    Session 1c. Software: The Future of Apps, Data & Cloud Services
    Mobile, Cloud, and Big Data are transforming our lives and businesses. Enjoy an interactive session with industry leaders on their views of key success factors in building enterprise products and services, SAAS vs perpetual business models, what make attractive M&A targets, and what are some upcoming disruptions.

     

    Session Chair:
    Mark Lee, , Co-Founder & CEO, Splashtop

     

    Panelists:
    Mark Lee, , Co-Founder & CEO, Splashtop (Moderator)
    Mark Rosenberg, Sr. Director Product Management, Oracle
    Jim Chow, Head of Global System Integrator Partnerships, Google Cloud Platform
    Yael Zheng, CMO, Tintri; ex-VP Marketing, VMware

     

    02:50-03:20 pm Networking Break

    03:20-04:30 pm Afternoon Program-II

    Session 1d. Hardware Die Hard
    Consumer hardware has dramatically evolved in the last decade with the advent of crowd-sourcing platforms allowing for quick validations of product-market-fit. We will dive into some of the enablers, influencers, and players that will bring about a new evolution of hardware.

     

    Session Chairs:
    David Jeng, VP of Operations and Distribution Sales, Wintec Industries
    C.Y. Chen, VP Global Manufacturing , Integrated Device Technology Inc.

     

    Panelists:
    Tobin Richardson, CEO & President of Zigbee Alliance
    Ben Bateman, Associate Director, Design & Technology Categories, Indiegogo
    Lucas Wang, Partner & CEO, HWTrek
    Mike Pegler, Advisory Principal, PWC

     

    Session 2. Venture Beats
    Recently, the “venture investment circulation” happens across the Pacific and between U.S. and Greater China. Some U.S. VCs want to do that, lest they miss out any potential huge IPO. From the other direction, China’s growing wealth and the government’s desire to attract tech companies have set the stage for VCs back by China’s funds to invest in more deals in the U.S. and also help the startups to market into China by leveraging those VC firms’ unique advantages. Discussion topics will be on the trend, what’s hot, and some of the notable cases.

     

    Session Chair: Tony Huang, Venture Partner, WI Harper Group

     

    Panelists:
    Hans Tung, Managing Partner, GGV Capital
    Steven Xi, Founder and Managing Partner, Eastlink Capital
    Andrew Tang, Managing Director, ABB Technology Ventures (ATV)

     

    Session 3. Cross-Pacific Dynamics
    The Development Status, Initiatives, Trends, and Opportunities in Asia and Cross-Pacific Activities.

     

    Session Chair:
    Sean Wang, Ph.D., President, ITRI International

     

    Panelists:
    Lucas Chang (Moderator), Ph.D., J.D., Partner, Morgan Lewis
    Charles Law, King & Wood Mallesons
    Robert Chen, Ph.D., President and CEO Aessense Corporation

     

    04:30-06:00 pm Walkabout @Shoreline, Putting @Shoreline, or Chatting in patio

    06:00-07:00 pm Dinner

    06:30-07:00 pm Monte Jade Official Matters

    07:00-07:30 pm Keynote Speech
    Speaker: Ro Khanna
    Topic: “Cross-Pacific Economic Partnership into the 21st Century-from Innovation to Advanced Manufacturing”

     

    07:30-09:00 pm Entertainment (dance floor opens)
    Performer: Major D

    No responses yet

    Sep 07 2014

    Monte Jade Tien’s Forum (Oct. 2014): Nature or Nurture? From the Rule of Jungle to the Incubator

    Published by admin under Tien Forum

    Bob

    Can entrepreneurs be trained? A slide show will reveal how the jungle (nature) works. Also what do most Incubators (nurture) offer. What is the best way to start a new company? Audience participates is welcomed.

     

     

    Speaker Bio:

    Chester Wang (王大成)

    T. Chester Wang serves as the Co-Chair of SVT Angels. He is a managing partner and co-founder of Acorn Campus Ventures and Acorn Angels. In 1984, he co-founded Pacific Rim Financial Corp, which has since developed numerous residential, commercial, and industrial properties in Silicon Valley, including the first Chinese-American shopping/residential center, Pacific Rim Plaza in San Jose. Later in 1994, he co-chaired San Jose’s New Realty Task Force with the Mayor to re-engineer the city’s budget and operation. Dr. Wang have served on the board of Good Samaritan Hospital, International Business Incubators, Joint Venture Silicon Valley, and the American Leadership Forum.

     

    Dr. Wang received a B.S. in Physics from Tsinghua University in Taiwan, a PhD in Physics from the University of Oregon, and previously served as a college professor in Computer Science for the University of Petroleum in Saudi Arabia.

     

    No responses yet

    Page: 1 2 3 ... 19